Searching for source:EMA

31,109 results
Record publications over time
Ironsift results are limited for unregistered users. Register or log in to see all records.

EU Clinical Trial 2018-004179-11 – EMA – Jun 3, 2019

Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, parallelgroup, superiority trial.

Main objective of the trial: To investigate the effectiveness of somatostatin analogues in decreasing the transfusion requirements in patients with HHT and GI bleeding who are refractory to endoscopic therapy.
Full record

EU Clinical Trial 2018-002474-52 – EMA – Jun 3, 2019

Multicenter randomized controlled phase 2 trial to evaluate AM-125 in the treatment of acute peripheral vertigo following vestibular schwannoma resection (TRAVERS)

Main objective of the trial: The primary objective of Part A is a. to explore and provide an estimate of the dose response curve for AM-125, and b. to evaluate the efficacy of AM-125 compared to placebo in reducing the symptoms of vestibular dysfunct...
Full record

EU Clinical Trial 2018-004539-54 – EMA – Jun 3, 2019

Capability of Tofacitinib or Etanercept to accelerate clinical relevant tapering of non-steroidal anti-inflammatory drugs and treat-to-target guided de-escalation of corticosteroids in patients with active Rheumatoid Arthrtis and an inadequate response to previous csDMARD therapy

Main objective of the trial: To demonstrate superiority in the proportion of patients who can discontinue Celecoxib treatment and in whom clinically relevant pain relief is measured, defined as reduction in VAS-pain (0-100 mm) of ≥ 30%, at week 12 co...
Full record

EU Clinical Trial 2019-001095-11 – EMA – May 31, 2019

RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF SHORT STATURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A MULTICENTER, OPEN-LABEL, CONCENTRATION-CONTROLLED TRIAL

Main objective of the trial: The objective of this study is to assess the effects of once daily dosing with rhIGF-1 in increasing height velocity in prepubertal subjects with growth failure associated with Primary IGF Deficiency.
Full record

EU Clinical Trial 2019-001020-36 – EMA – May 31, 2019

RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF PREPUBERTAL CHILDREN WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: A PHASE 3, RANDOMIZED, OPEN LABEL, OBSERVATION-CONTROLLED, MULTICENTER, PARALLEL-DOSE COMPARISON TRIAL.

Main objective of the trial: The primary objective of the study is to demonstrate the safety and efficacy of rhIGF-1 in promoting the growth of children with growth failure associated with Primary IGFD.
Full record

EU Clinical Trial 2019-000843-29 – EMA – May 31, 2019

Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 (rhIGF-1) Combination Therapy in Children with Short Stature Associated with IGF-1 Deficiency: A Six-year, Randomized, Multi-Center, Open-Label, Parallel-Group, Active Treatment Controlled, Dose Selection Trial

Main objective of the trial: Assess the efficacy and safety of three combinations of rhGH and rhIGF-1 compared to that of rhGH alone in the treatment of short stature associated with IGF-1 deficiency
Full record

EU Clinical Trial 2019-000853-30 – EMA – May 31, 2019

A Randomized, Double-Blind, Adaptive Trial with an Open-Label Treatment Extension to Determine the Efficacy and Safety of Topical DRGT-119 0.1% and 0.2% Gels in Patients with Chronic Anal Fissure

Main objective of the trial: Part 1: To demonstrate the efficacy of local application of varying strengths of DRGT-119 gels (0.1% and 0.2%) in patients with chronic anal fissure Part 2: To demonstrate the efficacy of a second cycle of DRGT-119 0.2% g...
Full record

EU Clinical Trial 2017-002804-29 – EMA – May 31, 2019

A MULTICENTER, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS

Main objective of the trial: Demonstrate the clinical efficacy of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNFα-IR) subjects with active Psoriatic Arthri...
Full record

EU Clinical Trial 2019-000844-81 – EMA – May 31, 2019

RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 (rhIGF-1) TREATMENT OF CHILDREN AND ADOLESCENTS WITH GROWTH FAILURE ASSOCIATED WITH PRIMARY IGF-1 DEFICIENCY: AN OPEN-LABEL, MULTI-CENTER, EXTENSION STUDY

Main objective of the trial: The primary objective of this extension study is to collect safety and efficacy data on the continued use of Increlex in children and adolescents treated for primary IGFD (height Standard Deviation Score (SDS) and IGF-1 S...
Full record

EU Clinical Trial 2018-004400-19 – EMA – May 30, 2019

Study of the effects of telomerase reactivation with Danazol on ovarian function. A Pilot Study.

Main objective of the trial: Define a pilot study to determine telomeric length distribution in granulosa cells to evaluate if telomerase reactivation via sexual steroids (DANAZOL), in patients with low ovarian reserve, is feasible. Estudio piloto pa...
Full record

EU Clinical Trial 2018-003008-38 – EMA – May 30, 2019

An Open-Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less Than 18 Years for the Treatment of Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension

Main objective of the trial: Part 1- To evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric subjects with RRMS -  To assess the PK of BIIB017 in pediatric subjects with RRMS The primary objective of Part 2 of the stud...
Full record
Register to view full records and use our APIs.

EU Clinical Trial 2018-004655-20 – EMA – May 30, 2019

CLINICAL EFFICACY OF INHIBITION OF ORGAN DYSFUNCTION THROUGH BERMEKIMAB IN SYSTEMIC SCLEROSIS: A PROOF-OF-CONCEPT DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL (THE LIGHT TRIAL)

Main objective of the trial: This is a proof-of concept RCT trying to generate evidence that inhibition of IL-1α through the administration of bermekimab may inhibit progression of SSc. Πρόκειται για μια κλινική μελέτη που προσπαθεί να διερευνήσει αν...
Full record

EU Clinical Trial 2018-004445-17 – EMA – May 30, 2019

A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients with Atrial Fibrillation

Main objective of the trial: The primary objective of the study is to demonstrate efficacy of AP30663 on the basis of the ability to convert AF following intravenous administration.
Full record

EU Clinical Trial 2018-004479-11 – EMA – May 30, 2019

A randomized, double-blind, placebo-controlled phase II multi-center study of intravenous MBG453 added to hypomethylating agents in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria

Main objective of the trial: - To determine if MBG453 combined with standard HMA therapy improves complete remission in subjects with intermediate, high, or very high risk MDS - To determine if MBG453 combined with standard HMA therapy improves PFS i...
Full record

EU Clinical Trial 2018-002676-40 – EMA – May 30, 2019

A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible

Main objective of the trial: - To compare the pCR rate of neoadjuvant nivolumab + NKTR-214 to Standard of Care (SOC, no neoadjuvant therapy) in all randomized participants - To compare the event-free survival (EFS) of neoadjuvant nivolumab + NKTR-214...
Full record

EU Clinical Trial 2018-003398-87 – EMA – May 30, 2019

A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH MODERATE ALZHEIMER’S DISEASE

Main objective of the trial: -To evaluate the effects of RO7105705 compared with placebo on cognition and function on the basis of Alzheimer’s Disease Assessment Scale, Cognitive Subscale, 11-item version (ADAS-Cog11) and Alzheimer's Disease Cooperat...
Full record

EU Clinical Trial 2018-004185-34 – EMA – May 29, 2019

A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination with Carfilzomib and Dexamethasone (DKd) Compared with Carfilzomib and Dexamethasone (Kd) in Participants with Multiple Myeloma who have been Previously Treated with Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment

Main objective of the trial: The primary objective is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of Dara-SC in combination with...
Full record

EU Clinical Trial 2018-003471-35 – EMA – May 29, 2019

A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus

Main objective of the trial: To characterize the long-term safety and tolerability of BMS-986165 in subjects with SLE
Full record

EU Clinical Trial 2019-000756-34 – EMA – May 29, 2019

The SANT - study A randomized controlled clinical trial of Streptococcus group A-negative acute tonsillitis in primary health care - a comparison of phenoxymethylpenicillin and no antibiotic treatment

Main objective of the trial: To determine if PcV compared to no antibiotic treatment (care as usual) reduces the duration of symptoms in patients with severe (Centor score 3-4), GAS-negative AT Att studera om PcV jämfört med ingen antibiotika behandl...
Full record

EU Clinical Trial 2019-001199-12 – EMA – May 28, 2019

Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Patients With Moderately or Severely Active Crohn's Disease

Main objective of the trial: To evaluate efficacy of MLN0002 in induction and maintenance therapy in Japanese subjects with moderately or severely active Crohn's disease.
Full record

EU Clinical Trial 2018-003615-22 – EMA – May 28, 2019

Efficacy and safety of twice-daily application of delgocitinib cream 20 mg/g for 6 weeks in subjects with active discoid lupus erythematosus. A phase 2a exploratory, randomised, double-blind, vehicle-controlled, within-subject, multi-centre trial.

Main objective of the trial: To investigate the efficacy of delgocitinib cream 20 mg/g twice daily on active DLE target lesions.
Full record
Register to view full records and advanced analytics.

EU Clinical Trial 2019-001198-10 – EMA – May 28, 2019

A Phase 3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Subjects with Moderate or Severe Ulcerative Colitis

Main objective of the trial: To evaluate efficacy of MLN0002 in induction and maintenance therapy in Japanese subjects with moderate or severe UC.
Full record

EU Clinical Trial 2017-002369-23 – EMA – May 27, 2019

A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 28-week treatment period as adjunctive therapy to antipsychotic treatment for the prevention of relapse in patients with schizophrenia.

Main objective of the trial: The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 25mg and 50mg once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment....
Full record

EU Clinical Trial 2017-003344-21 – EMA – May 27, 2019

An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

Main objective of the trial: To compare the overall survival (OS) of subjects with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of subjects treated with chemotherapy
Full record

EU Clinical Trial 2019-002189-11 – EMA – May 27, 2019

A Phase 2, Randomized, Placebo-Controlled, Double-blind Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Main objective of the trial: To evaluate the treatment effect of VX-661 in combination with ivacaftor (VX-661/ivacaftor) on chest imaging endpoints as evaluated using low-dose computed tomography (LDCT) at Week 72 in subjects with cystic fibrosis (CF...
Full record

EU Clinical Trial 2018-001926-25 – EMA – May 27, 2019

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis

Main objective of the trial: 1. Assess whether BMS-986165 is superior to placebo at Week 16 in the treatment of subjects with moderate-to-severe plaque psoriasis Évaluer si le BMS-986165 est supérieur au placebo à la semaine 16 pour le traitement de...
Full record

EU Clinical Trial 2018-004378-92 – EMA – May 27, 2019

Effect of cannabinoids (THC / CBD) on hyperalgesia in patients with deep endometriosis

Main objective of the trial: Demonstrate that cannabinoid treatment decreases hyperalgesia in patients with deep endometriosis Demostrar que el tratamiento con cannabinoides disminuye la hiperalgesia en pacientes con endometriosis profunda
Full record

EU Clinical Trial 2018-002896-17 – EMA – May 27, 2019

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies

Main objective of the trial: 1. To evaluate the objective response rate (ORR) of ME-401 in relapsed FL, defined as the best response rating of complete response (CR) or partial response (PR) according to the Lugano Response Criteria , as determined b...
Full record

EU Clinical Trial 2018-002114-13 – EMA – May 24, 2019

Efficacy of Colchicine to prevent skin relapses in adult's IgA vasculitis

Main objective of the trial: Evaluation of efficacy of colchicine versus placebo to prevent cutaneous relapses, 6 months after inclusion, in adult patients with cutaneous IgA vasculitis alone or associated with non-severe digestive or renal involveme...
Full record

EU Clinical Trial 2018-001275-21 – EMA – May 24, 2019

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Twice-Daily Oral Administration of a Peripherally Acting Dopamine Receptor D2/D3 Antagonist, TAK-906 for the Treatment of Adult Subjects With Symptomatic Idiopathic or Diabetic Gastroparesis

Main objective of the trial: To assess the efficacy of treatment with various dose levels of TAK-906 in adult subjects with gastroparesis compared with placebo during 12 weeks of treatment.
Full record

EU Clinical Trial 2018-002292-18 – EMA – May 24, 2019

CT air-trapping characterization for the early identification of Benralizumab responders among eosinophilic asthma patients

Main objective of the trial: The primary objective of this study is to determine the prognostic value (sensitivity and specificity) of air-trapping measures (Expiratory/Inspiratory Mean Lung Density) detected via quantitative thoracic computed tomogr...
Full record
Register to view full records and disable ads.

EU Clinical Trial 2018-004792-13 – EMA – May 23, 2019

A randomized, double-blind, placebo controlled, parallel group, multicentric, phase IIa clinical trial to evaluate the safety, tolerability and therapeutic efficacy of daily oral treatment with NFX88 on neuropathic pain in patients with spinal cord injury.

Main objective of the trial: The primary objective is to assess the safety and tolerability of NFX88 in spinal cord injury patients with neuropathic pain over ninety-day treatment period. El objetivo principal del ensayo será evaluar la seguridad y l...
Full record

EU Clinical Trial 2018-003096-35 – EMA – May 23, 2019

Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome (GRACE): A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant

Main objective of the trial: • To assess the efficacy of relacorilant for the treatment of endogenous Cushing syndrome based on glycemic control and BP control during the Randomized-Withdrawal (RW) phase • To assess the safety of relacorilant for the...
Full record

EU Clinical Trial 2018-004411-49 – EMA – May 23, 2019

.

Main objective of the trial: Montrer que le changement de traitement (switch) anti-TNFα vers un biosimilaire de l’infliximab (Inflectra®) n’est pas inférieur en termes d’efficacité sur l’activité inflammatoire intestinale, à la poursuite du médicamen...
Full record

EU Clinical Trial 2018-000383-28 – EMA – May 23, 2019

Perioperative chemotherapy vs. immunotherapy vs. chemo-immunotherapy stratified by early response evaluation in patients with advanced gastric cancer (GC) and adenocarcinoma of the esophago-gastric junction (AEG) (IMAGINE)

Main objective of the trial: Primary endpoint is the rate of pathological complete responses (pCR) as determined by pathological examination of the resected tumor following preoperative systemic therapy. A pCR rate of 15% is expected in Arm A with FL...
Full record

EU Clinical Trial 2018-003558-26 – EMA – May 23, 2019

A randomized, double blind, placebo controlled, parallel group, multiple dose, induction study to evaluate the safety, tolerability and optimal dose of ABX464 compared with placebo in patients with moderate to severe ulcerative colitis who have inadequate response, loss of response, or intolerance with at least one of the following agents: immunosuppressant treatment (i.e. azathioprine, 6-mercaptopurine, methotrexate), tumor necrosis factor alpha [TNF-α] inhibitors, vedolizumab, JAK inhibitors and/or corticosteroid treatment.

Main objective of the trial: The primary objective of the study is to determine an optimal ABX464 dose to be used in moderate to severe active ulcerative colitis patients who have failed or are intolerant to immunomodulators, Anti-TNFα, vedolizumab,...
Full record

EU Clinical Trial 2018-001284-24 – EMA – May 22, 2019

A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients with Relapsed or Refractory Marginal Zone Lymphoma

Main objective of the trial: To evaluate the efficacy of zanubrutinib in relapsed or refractory marginal zone lymphoma as measured by overall response rate in accordance with the Lugano Classification determined by independent central review
Full record

EU Clinical Trial 2018-004223-36 – EMA – May 22, 2019

A Randomised, Double-blind, Parallel-group, Phase III Study to Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) with MabThera® in Subjects with Previously Untreated, Stage II-IV, Cluster of Differentiation (CD)20-Positive, Low Tumour Burden Follicular Lymphoma

Main objective of the trial: The primary objective of the current study is to demonstrate the equivalent efficacy of DRL_RI and MabThera® in subjects with cluster of differentiation (CD)20-positive, low tumour burden follicular lymphoma (LTB-FL) in t...
Full record

EU Clinical Trial 2015-003166-91 – EMA – May 22, 2019

A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naïve severe aplastic anemia or recurrent aplastic anemia.

Main objective of the trial: To characterize the PK of eltrombopag at steady state after oral administration in pediatric patients with SAA.
Full record

EU Clinical Trial 2017-002322-20 – EMA – May 22, 2019

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, ACTIVE REFERENCE (ADALIMUMAB) STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS

Main objective of the trial: Demonstrate the clinical efficacy of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA), as assessed by the American College of Rheumatolo...
Full record

EU Clinical Trial 2018-003958-25 – EMA – May 22, 2019

Screening for cancer with PET / CT in patients with unprovoked venous thromboembolic disease with a high risk of developing cancer. Open randomized clinical trial.

Main objective of the trial: Estimate the impact of an active cancer search strategy using PET-CT in the number of neoplasms diagnosed in the screening process in patients with high-risk unprovoked thromboembolic disease. Estimar el impacto de una es...
Full record
Register to view full records and receive email notifications.

EU Clinical Trial 2018-002344-81 – EMA – May 22, 2019

An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy

Main objective of the trial: The aim of this study is to assess the efficacy of BI 754091 in combination with other checkpoint inhibitors or anticancer medications in diverse tumour type cohorts.
Full record

EU Clinical Trial 2018-003146-17 – EMA – May 21, 2019

A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction

Main objective of the trial: Comparison of the effects of twice daily (bis in die [BID]) oral administration of 2 doses of firibastat to those of BID oral administration of ramipril on the change from Baseline in left ventricular ejection fraction (L...
Full record

EU Clinical Trial 2018-003243-39 – EMA – May 21, 2019

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

Main objective of the trial: To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the Myasthenia Gravis-Activities of Daily Living (MG-ADL) profile. Evaluar la eficacia de ravulizumab en comp...
Full record

EU Clinical Trial 2018-004372-36 – EMA – May 21, 2019

A phase IIa, multicenter, Open-Label Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients with Metastatic Pancreatic Cancer, the COMBAT study

Main objective of the trial: to assess the efficacy and safety of BL-8040 in combination with pembrolizumab and BL8040/ Pembrolizumab in combination with liposomal irinotecan (Onivyde®)/5-fluorouracil/leucovorin (5-FU/LV) in subjects with metastatic...
Full record

EU Clinical Trial 2018-003748-22 – EMA – May 21, 2019

PRISM: An Open-label, Multi-Center Extension Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) Following Systemic Treatment in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype, Who Have Completed the SOLAR Study

Main objective of the trial: The primary objective of the study is to evaluate the efficacy of cobomarsen in subjects with MF who have shown disease progression following treatment with vorinostat in the SOLAR study. El objetivo principal del estudio...
Full record

EU Clinical Trial 2018-002932-26 – EMA – May 21, 2019

A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination with Novel Agents in Subjects with Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)

Main objective of the trial: Efficacy - Assess the antitumor activity of durvalumab alone and/or in combination with novel agents Eficacia - Evaluar la actividad antitumoral de durvalumab en monoterapia y/o en combinación con fármacos innovadores
Full record

EU Clinical Trial 2019-001343-44 – EMA – May 21, 2019

Conventional ovarian stimulation vs. stimulation with single injection of Corifollitropin alfa in oocyte donors. Randomized clinical trial. Tail Studio

Main objective of the trial: To study the efficiency of the use of a single injection of CFA for ovarian stimulation, initiating administration late and without further contribution of FSH activity after the 7th day of stimulation compared to convent...
Full record

EU Clinical Trial 2018-000504-42 – EMA – May 21, 2019

A Phase I/II Open Label, Single-dose, Gene Transfer Study of scAAV9.U1a.hSGSH (ABO-102) in Patients with Middle and Advanced Phases of MPS IIIA Disease

Main objective of the trial: Primary outcomes of safety and efficacy assessed by measuring biochemical and biophysical changes in middle and advanced phases of MPS IIIA evolution Objetivos principales de seguridad y eficacia evaluado a través de los...
Full record

EU Clinical Trial 2017-001249-28 – EMA – May 21, 2019

Phase III, Single-blinded, placebo-Controlled and randomized Clinical Trial with minimal intervention on the Treatment with Plasma Rich in Growth Factors (PRGF) of Work-site Acute Epicondylitis Resistant to Conservative Treatment

Main objective of the trial: Primary Objective: To determine whether using autologous conditioned platelet-rich plasma with growth factor is more efficacious than betametasone or physiologic serum infiltration in patients refractory o conservative tr...
Full record